Bipolar Disorder
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Propensity score-based nonparametric test revealing genetic variants underlying bipolar disorder.
|
21254220 |
2011 |
Bipolar Disorder
|
0.100 |
GeneticVariation
|
disease |
GWASDB |
Propensity score-based nonparametric test revealing genetic variants underlying bipolar disorder.
|
21254220 |
2011 |
Red Blood Cell Count measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
Finding of Mean Corpuscular Hemoglobin
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
Lymphoma
|
0.020 |
GeneticVariation
|
group |
BEFREE |
A biallelic EcoRI polymorphism of cdc25B gene was identified with a similar distribution in patients with lymphoma and in a normal population. cdc25A was overexpressed in three aggressive lymphomas.
|
9563496 |
1998 |
Non-Small Cell Lung Carcinoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
54 potentially functional polymorphisms in key cell cycle genes (CDK1, CDK2, CDK4, CDK6, CDK7, CCND1, CCND2, CCND3, CCNE1, CCNA1, CCNA2, CCNB1, CCNH, p15, p16, p18, p19, p21, p27, Cdc25A and Cdc25B) were genotyped by using Illumina SNP genotyping platform to evaluate their associations with survival of NSCLC in a clinical cohort of 568 patients.
|
21145615 |
2011 |
Adult Lymphoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
A biallelic EcoRI polymorphism of cdc25B gene was identified with a similar distribution in patients with lymphoma and in a normal population. cdc25A was overexpressed in three aggressive lymphomas.
|
9563496 |
1998 |
Childhood Lymphoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
A biallelic EcoRI polymorphism of cdc25B gene was identified with a similar distribution in patients with lymphoma and in a normal population. cdc25A was overexpressed in three aggressive lymphomas.
|
9563496 |
1998 |
Hepatitis, Toxic
|
0.300 |
Biomarker
|
disease |
CTD_human |
Characterization of chemically induced liver injuries using gene co-expression modules.
|
25226513 |
2014 |
Drug-Induced Liver Disease
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Characterization of chemically induced liver injuries using gene co-expression modules.
|
25226513 |
2014 |
Heart Failure, Diastolic
|
0.300 |
Biomarker
|
disease |
CTD_human |
In Silico Analysis of Differential Gene Expression in Three Common Rat Models of Diastolic Dysfunction.
|
29556499 |
2018 |
Hepatitis, Drug-Induced
|
0.300 |
Biomarker
|
disease |
CTD_human |
Characterization of chemically induced liver injuries using gene co-expression modules.
|
25226513 |
2014 |
Drug-Induced Acute Liver Injury
|
0.300 |
Biomarker
|
disease |
CTD_human |
Characterization of chemically induced liver injuries using gene co-expression modules.
|
25226513 |
2014 |
Chemical and Drug Induced Liver Injury
|
0.300 |
Biomarker
|
disease |
CTD_human |
Characterization of chemically induced liver injuries using gene co-expression modules.
|
25226513 |
2014 |
Chemically-Induced Liver Toxicity
|
0.300 |
Biomarker
|
disease |
CTD_human |
Characterization of chemically induced liver injuries using gene co-expression modules.
|
25226513 |
2014 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CDC25B is a cell-cycle regulatory protein, which is considered to be related to tumorigenesis and progression of tumours.
|
16803948 |
2006 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CDC25A (+), as well as CDC25B (+), was more frequently found in patients with deeper tumour invasion and lymph node metastasis, while tumour size was correlated only with CDC25A expression.
|
11487274 |
2001 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Several DSPs, mainly MKPs and, unexpectedly, MTMRs, were altered following HER2-modulation in cells and 3 DSPs (DUSP6, CDC25B and MTMR11) were altered in both cells and tumors.
|
20413845 |
2010 |
Carcinogenesis
|
0.070 |
Biomarker
|
phenotype |
BEFREE |
In the tumor initiation, the opposite role of YWHAE and CDC25B in gastric carcinogenesis seems to be independent of MYC expression.
|
27863420 |
2016 |
Carcinogenesis
|
0.070 |
Biomarker
|
phenotype |
BEFREE |
Inhibition of CDC25B With WG-391D Impedes the Tumorigenesis of Ovarian Cancer.
|
31024841 |
2019 |
Carcinogenesis
|
0.070 |
Biomarker
|
phenotype |
BEFREE |
Both CDC25B and PED/PEA-15 play a certain role in the carcinogenesis of esophageal cancer, and PED/PEA-15 has a greater influence on postoperative survival time.
|
25775393 |
2015 |
Carcinogenesis
|
0.070 |
Biomarker
|
phenotype |
BEFREE |
CDC25B is a cell-cycle regulatory protein, which is considered to be related to tumorigenesis and progression of tumours.
|
16803948 |
2006 |
Carcinogenesis
|
0.070 |
Biomarker
|
phenotype |
BEFREE |
Collectively, our study demonstrate that KCTD12 binds to CDC25B and activates CDK1 and Aurora A to facilitate the G2/M transition and promote tumorigenesis and that Aurora A phosphorylates KCTD12 at serine 243 to trigger a positive feedback loop, thereby potentiating the effects of KCTD12.
|
28869606 |
2017 |
Tumor Cell Invasion
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
Moreover, we demonstrated that miR-214 inhibited Eca9706 and Eca109 cells proliferation and invasion through CDC25B.
|
28954387 |
2017 |
Tumor Cell Invasion
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
CDC25A (+), as well as CDC25B (+), was more frequently found in patients with deeper tumour invasion and lymph node metastasis, while tumour size was correlated only with CDC25A expression.
|
11487274 |
2001 |